2024 13th International Conference on Cold Chain Pharmaceutical Supply Chain Concludes Successfully

As an industry leader, Guangzhou Jingrui Intelligent Technology Co., Ltd. was invited to attend and gathered with industry leaders to discuss and plan the future of the industry. The conference was themed "Collaborative Symbiosis: Linking Value," directly addressing the core needs and challenges of industry development. The event attracted over 400 companies and more than 800 industry elites, jointly contributing ideas for the high-quality development of the cold chain pharmaceutical supply chain.

The conference featured a variety of formats, including keynote speeches, roundtable discussions, salon workshops, and on-site visits, breaking down barriers to industry communication and providing a deep exchange and learning platform for experts in the global cold chain pharmaceutical supply chain field. Participants discussed future trends in the circulation of temperature-controlled products and jointly promoted innovation and progress in the cold chain pharmaceutical supply chain industry.

With the in-depth implementation of the "Healthy China" strategy, the pharmaceutical cold chain industry is experiencing unprecedented development opportunities. The industry scale continues to expand, regulatory enforcement is constantly strengthening, infrastructure is improving, and emerging business models are flourishing. Faced with new challenges, how to build a new development pattern, improve supply chain management systems, and enhance corporate operational efficiency and management levels has become the industry's common focus.

At this critical juncture, industry companies should drive innovation, empower themselves with digital intelligence technologies, achieve deep integration of the industrial chain, adhere to green and low-carbon development, and strategically expand into global markets. We look forward to jointly stimulating new growth momentum in the cold chain pharmaceutical supply chain, drawing a new blueprint for the global development of the cold chain pharmaceutical supply chain, and contributing to the construction of a healthier, safer, and more efficient pharmaceutical cold chain ecosystem.